Department of Hematology, Centre Hospitalier Universitaire de Nantes, Nantes, France;
Service d'Hématologie, Hopital Purpan, Toulouse, France; and.
Blood. 2015 May 14;125(20):3076-84. doi: 10.1182/blood-2014-09-568915. Epub 2015 Apr 2.
In the past decade, one of the major advances in the management of patients with symptomatic newly diagnosed multiple myeloma has been the introduction of novel agents, thalidomide, bortezomib, and lenalidomide, as part of frontline treatment in both transplant and nontransplant candidates. These drugs have markedly improved the rate of complete remission, and time to progression, progression-free survival, and overall survival have significantly increased. This article focuses on more recent frontline therapeutic approaches both in older patients, not eligible for high-dose therapy and autologous stem cell transplantation (ASCT), and in younger patients eligible for early ASCT.
在过去的十年中，在管理有症状的新诊断多发性骨髓瘤患者方面的主要进展之一是将新型药物沙利度胺、硼替佐米和来那度胺作为一线治疗药物（适用于移植候选者和非移植候选者）引入。这些药物显著提高了完全缓解率，并且进展时间、无进展生存期和总生存期均显著提高。本文主要关注在不适合大剂量治疗和自体干细胞移植（ASCT）的老年患者以及适合早期 ASCT 的年轻患者中，最近的一线治疗方法。
